<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150927024228N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-10-22</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of leech therapy in diabetic neuropathy of lower limbs</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of leech therapy in diabetic neuropathy of lower limbs</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-08-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50237</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done in a simple way using a table of random numbers. Among the numbers 1 to 40, 20 random numbers are selected from this table for the leech therapy and the rest (of the patients) are assigned to the standard treatment group. Patients are not known in advance. In this way, the order of entering the groups is determined: for example, it is pre-determined and it is written in the envelopes, for example, which group the 5th, 30th or 40th person will be in. When each person enters the study, an envelope is opened and the treatment group is determined for him. Sorting is done using a table of random numbers. some envelopes are provided according to the number of samples and the type of treatment is written in each envelope. We start reading from a point on the table of random numbers vertically and in two digits two digits. If the read number was between 01 and 40, the number is assigned to the leech therapy group. We will continue this work until we reach the number of samples in this group (20 people). the envelopes are closed and sealed and a three-digit code is written on each of them. the order of the envelopes is determined by a statistician. after the patient enters the study and completes the informed consent form, an envelope is opened and the type of treatment is determined; then the patient receives the treatment.</study_design>
      <phase>3</phase>
      <hc_freetext>Diabetic neuropathy.</hc_freetext>
      <i_freetext>Intervention 1: In the leech treatment group, three to five medical leeches, six to eight centimeters in size, are thrown in three steps every fifteen days in the area of the back of the feet, tangentially from the root of the second toe to the external malleolus. Intervention 2: In the control group, patients are given 300 mg of gabapentin capsule as a single dose at night before going to bed for 30 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After the study, information about the main outcome will be shared.

When:
12 months after printing

To whom:
All researchers can get it.

Conditions:
Data and results will be available to all researchers for research on diabetic neuropathy.

Where to obtain:
dr.azimm@gmail.com

How to obtain:
The data will be provided to the applicant within one month after reviewing and confirming the application.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farshad Alami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nasiraei8, Sardaran 9, Sheikh Tabarsi Street</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4713937679</zip>
        <telephone>+98 11 3229 2492</telephone>
        <email>farshad.alami1700@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Azimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Amirkabir Crossroad, Jomhuri Boulevard, Kerman</address>
        <city>kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3211 0123</telephone>
        <email>Dr.azimm@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having informed consent
Age 30 years and above
Type 2 diabetes with the approval of an endocrinologist
Having diabetic neuropathy based on nerve and muscle tape
The patient should not use other drugs that are effective on neuropathy at the same time
No pregnancy
No breastfeeding
No other diseases that cause neuropathy such as alcohol, vitamin B12 deficiency, chemotherapy, kidney failure, nerve compression, autoimmune disease, infection, Guillain-Barre syndrome</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having a diabetic foot ulcer requires surgery
Use of anticoagulants such as heparin, warfarin, etc
Any coagulation disease
History of hospitalization due to cardiovascular disease
History of major mental disorders
Not taking painkillers, or common drugs for neuropathy treatment during the last month
Anemia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11.40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus with diabetic neuropathy, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the leech treatment group, three to five medical leeches, six to eight centimeters in size, are thrown in three steps every fifteen days in the area of the back of the feet, tangentially from the root of the second toe to the external malleolus.</i_keyword>
      <i_keyword>In the control group, patients are given 300 mg of gabapentin capsule as a single dose at night before going to bed for 30 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Burning sensation. Timepoint: At the beginning of the study, days 15, 30 and 45 of the beginning of the study. Method of measurement: Using Visual Analogue Scale and Neurophathy Symptom Score questionnaires.</prim_outcome>
      <prim_outcome>Intensity of pain. Timepoint: At the beginning of the study, days 15, 30 and 45 of the beginning of the study. Method of measurement: Using Visual Analogue Scale and  Neurophathy Symptom Score questionnaires.</prim_outcome>
      <prim_outcome>Tingling. Timepoint: At the beginning of the study, days 15, 30 and 45 of the beginning of the study. Method of measurement: Visual Analogue scale and neuropathy symptom score questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Muscle weakness and cramps. Timepoint: At the beginning of the study, days 15, 30 and 45 after the start of the study. Method of measurement: Neoropathy Symptom Score questionnaire.</sec_outcome>
      <sec_outcome>Vibration in the big toe. Timepoint: At the beginning of the study, days 15, 30 and 45 after the start of the study. Method of measurement: Neurophathy Disability Score questionnaire.</sec_outcome>
      <sec_outcome>Recognize the feeling of cold and heat in the back of the legs. Timepoint: At the beginning of the study, days 15, 30 and 45 after the start of the study. Method of measurement: Neurophathy Disability Score questionnaire.</sec_outcome>
      <sec_outcome>Detect sharp and blunt bodies on the big toe. Timepoint: At the beginning of the study, days 15, 30 and 45 after the start of the study. Method of measurement: Neurophathy Disability Score questionnaire.</sec_outcome>
      <sec_outcome>Presence or absence of Achilles reflex. Timepoint: At the beginning of the study, days 15, 30 and 45 after the start of the study. Method of measurement: Neurophathy Disabilities score questionnaire.</sec_outcome>
      <sec_outcome>Possible repair of foot nerves in its treatment with leeches. Timepoint: Before the start of the study and 45 days after the start of the study. Method of measurement: Nerve conduction velocity.</sec_outcome>
      <sec_outcome>Possible repair of foot nerves in drug treatment. Timepoint: Before the start of the study and 45 days after the start of the study. Method of measurement: Nerve conduction velocity.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-08-04</approval_date>
        <contact_name>Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Shafa Crossroad, Jomhuri Boulevard, Kerman Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
